ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
80,600
+2,800 (3.60%)
May 30, 2025, 3:30 PM KST
248.92%
Market Cap 3.91T
Revenue (ttm) 27.63B
Net Income (ttm) -71.71B
Shares Out 48.53M
EPS (ttm) -1,489.49
PE Ratio n/a
Forward PE 94.90
Dividend n/a
Ex-Dividend Date n/a
Volume 1,462,236
Average Volume 1,038,570
Open 80,700
Previous Close 77,800
Day's Range 78,600 - 83,500
52-Week Range 21,200 - 84,000
Beta 1.08
RSI 70.41
Earnings Date Aug 11, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.